Drug Profile
Research programme: monoclonal antibody therapeutics - Adienne
Alternative Names: SAND5; SAND5 RGDLatest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator ADIENNE
- Class Monoclonal antibodies
- Mechanism of Action Complement C5 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Inflammation; Ischaemia; Reperfusion injury
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Inflammation in Italy (Parenteral)
- 16 Jul 2016 No recent reports of development identified for preclinical development in Ischaemia in Italy (Parenteral)
- 16 Jul 2016 No recent reports of development identified for preclinical development in Reperfusion-injury in Italy (Parenteral)